Minireviews
Copyright ©The Author(s) 2022.
World J Gastroenterol. Aug 28, 2022; 28(32): 4540-4556
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4540
Figure 17
Figure 17  LR-5 observation. A and B: Axial post-contrast images arterial (A) and portal phase (B) showed an ablation defect in segment VI without residual areas of arterial enhancement or washout. This was classified as LR-treatment response non-viable; C-E: Later pre-contrast (C) arterial (D) and portal (E) phase showed a new nodule (arrows) measuring 12 mm with strong arterial enhancement and washout categorized as LR-5. If a new tumor arises within or adjacent to a treated lesion, this observation should be assigned a new non-treated LI-RADS category.